Cargando…

Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh

Cholera caused by Vibrio cholerae O139 emerged in the early 1990s and spread rapidly to 11 Asian countries before receding for unclear reasons. Protection against cholera is serogroup-specific, which is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS). V. cholerae...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaisar, M. Hasanul, Kelly, Meagan, Kamruzzaman, Mohammad, Bhuiyan, Taufiqur R., Chowdhury, Fahima, Khan, Ashraful Islam, LaRocque, Regina C., Calderwood, Stephen B., Harris, Jason B., Charles, Richelle C., Čížová, Alžbeta, Mečárová, Jana, Korcová, Jana, Bystrický, Slavomír, Kováč, Pavol, Xu, Peng, Qadri, Firdausi, Ryan, Edward T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597347/
https://www.ncbi.nlm.nih.gov/pubmed/37646517
http://dx.doi.org/10.1128/msphere.00255-23
_version_ 1785125318757974016
author Kaisar, M. Hasanul
Kelly, Meagan
Kamruzzaman, Mohammad
Bhuiyan, Taufiqur R.
Chowdhury, Fahima
Khan, Ashraful Islam
LaRocque, Regina C.
Calderwood, Stephen B.
Harris, Jason B.
Charles, Richelle C.
Čížová, Alžbeta
Mečárová, Jana
Korcová, Jana
Bystrický, Slavomír
Kováč, Pavol
Xu, Peng
Qadri, Firdausi
Ryan, Edward T.
author_facet Kaisar, M. Hasanul
Kelly, Meagan
Kamruzzaman, Mohammad
Bhuiyan, Taufiqur R.
Chowdhury, Fahima
Khan, Ashraful Islam
LaRocque, Regina C.
Calderwood, Stephen B.
Harris, Jason B.
Charles, Richelle C.
Čížová, Alžbeta
Mečárová, Jana
Korcová, Jana
Bystrický, Slavomír
Kováč, Pavol
Xu, Peng
Qadri, Firdausi
Ryan, Edward T.
author_sort Kaisar, M. Hasanul
collection PubMed
description Cholera caused by Vibrio cholerae O139 emerged in the early 1990s and spread rapidly to 11 Asian countries before receding for unclear reasons. Protection against cholera is serogroup-specific, which is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS). V. cholerae O139 also expresses the OSP-capsule. We, therefore, assessed antibody responses targeting V. cholerae O139 OSP, LPS, capsule, and vibriocidal responses in patients in Bangladesh with cholera caused by V. cholerae O139. We compared these responses to those of age-gender-blood group-matched recipients of the bivalent oral cholera vaccine (OCV O1/O139). We found prominent OSP, LPS, and vibriocidal responses in patients, with a high correlation between these responses. OSP responses primarily targeted the terminal tetrasaccharide of OSP. Vaccinees developed OSP, LPS, and vibriocidal antibody responses, but of significantly lower magnitude and responder frequency (RF) than matched patients. We separately analyzed responses in pediatric vaccinees born after V. cholerae O139 had receded in Bangladesh. We found that OSP responses were boosted in children who had previously received a single dose of bivalent OCV 3 yr previously but not in vaccinated immunologically naïve children. Our results suggest that OSP-specific responses occur during cholera caused by V. cholerae O139 despite the presence of capsules, that vaccination with bivalent OCV is poorly immunogenic in the short term in immunologically naïve individuals, but that OSP-specific immune responses can be primed by previous exposure, although whether such responses can protect against O139 cholera is uncertain. IMPORTANCE: Cholera is a severe dehydrating illness in humans caused by Vibrio cholerae serogroups O1 or O139. Protection against cholera is serogroup-specific, which is defined by the O-specific polysaccharide (OSP) of V. cholerae LPS. Yet, little is known about immunity to O139 OSP. In this study, we assessed immune responses targeting OSP in patients from an endemic region with cholera caused by V. cholerae O139. We compared these responses to those of the age-gender-blood group-matched recipients of the bivalent oral cholera vaccine. Our results suggest that OSP-specific responses occur during cholera caused by V. cholerae O139 and that the OSP responses primarily target the terminal tetrasaccharide of OSP. Our results further suggest that vaccination with the bivalent vaccine is poorly immunogenic in the short term for inducing O139-specific OSP responses in immunologically naïve individuals, but OSP-specific immune responses can be primed by previous exposure or vaccination.
format Online
Article
Text
id pubmed-10597347
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-105973472023-10-25 Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh Kaisar, M. Hasanul Kelly, Meagan Kamruzzaman, Mohammad Bhuiyan, Taufiqur R. Chowdhury, Fahima Khan, Ashraful Islam LaRocque, Regina C. Calderwood, Stephen B. Harris, Jason B. Charles, Richelle C. Čížová, Alžbeta Mečárová, Jana Korcová, Jana Bystrický, Slavomír Kováč, Pavol Xu, Peng Qadri, Firdausi Ryan, Edward T. mSphere Research Article Cholera caused by Vibrio cholerae O139 emerged in the early 1990s and spread rapidly to 11 Asian countries before receding for unclear reasons. Protection against cholera is serogroup-specific, which is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS). V. cholerae O139 also expresses the OSP-capsule. We, therefore, assessed antibody responses targeting V. cholerae O139 OSP, LPS, capsule, and vibriocidal responses in patients in Bangladesh with cholera caused by V. cholerae O139. We compared these responses to those of age-gender-blood group-matched recipients of the bivalent oral cholera vaccine (OCV O1/O139). We found prominent OSP, LPS, and vibriocidal responses in patients, with a high correlation between these responses. OSP responses primarily targeted the terminal tetrasaccharide of OSP. Vaccinees developed OSP, LPS, and vibriocidal antibody responses, but of significantly lower magnitude and responder frequency (RF) than matched patients. We separately analyzed responses in pediatric vaccinees born after V. cholerae O139 had receded in Bangladesh. We found that OSP responses were boosted in children who had previously received a single dose of bivalent OCV 3 yr previously but not in vaccinated immunologically naïve children. Our results suggest that OSP-specific responses occur during cholera caused by V. cholerae O139 despite the presence of capsules, that vaccination with bivalent OCV is poorly immunogenic in the short term in immunologically naïve individuals, but that OSP-specific immune responses can be primed by previous exposure, although whether such responses can protect against O139 cholera is uncertain. IMPORTANCE: Cholera is a severe dehydrating illness in humans caused by Vibrio cholerae serogroups O1 or O139. Protection against cholera is serogroup-specific, which is defined by the O-specific polysaccharide (OSP) of V. cholerae LPS. Yet, little is known about immunity to O139 OSP. In this study, we assessed immune responses targeting OSP in patients from an endemic region with cholera caused by V. cholerae O139. We compared these responses to those of the age-gender-blood group-matched recipients of the bivalent oral cholera vaccine. Our results suggest that OSP-specific responses occur during cholera caused by V. cholerae O139 and that the OSP responses primarily target the terminal tetrasaccharide of OSP. Our results further suggest that vaccination with the bivalent vaccine is poorly immunogenic in the short term for inducing O139-specific OSP responses in immunologically naïve individuals, but OSP-specific immune responses can be primed by previous exposure or vaccination. American Society for Microbiology 2023-08-30 /pmc/articles/PMC10597347/ /pubmed/37646517 http://dx.doi.org/10.1128/msphere.00255-23 Text en Copyright © 2023 Kaisar et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Kaisar, M. Hasanul
Kelly, Meagan
Kamruzzaman, Mohammad
Bhuiyan, Taufiqur R.
Chowdhury, Fahima
Khan, Ashraful Islam
LaRocque, Regina C.
Calderwood, Stephen B.
Harris, Jason B.
Charles, Richelle C.
Čížová, Alžbeta
Mečárová, Jana
Korcová, Jana
Bystrický, Slavomír
Kováč, Pavol
Xu, Peng
Qadri, Firdausi
Ryan, Edward T.
Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title_full Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title_fullStr Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title_full_unstemmed Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title_short Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
title_sort comparison of o-specific polysaccharide responses in patients following infection with vibrio cholerae o139 versus vaccination with a bivalent (o1/o139) oral killed cholera vaccine in bangladesh
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597347/
https://www.ncbi.nlm.nih.gov/pubmed/37646517
http://dx.doi.org/10.1128/msphere.00255-23
work_keys_str_mv AT kaisarmhasanul comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT kellymeagan comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT kamruzzamanmohammad comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT bhuiyantaufiqurr comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT chowdhuryfahima comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT khanashrafulislam comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT larocquereginac comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT calderwoodstephenb comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT harrisjasonb comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT charlesrichellec comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT cizovaalzbeta comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT mecarovajana comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT korcovajana comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT bystrickyslavomir comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT kovacpavol comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT xupeng comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT qadrifirdausi comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh
AT ryanedwardt comparisonofospecificpolysaccharideresponsesinpatientsfollowinginfectionwithvibriocholeraeo139versusvaccinationwithabivalento1o139oralkilledcholeravaccineinbangladesh